Nombre del producto:1-(5-Bromo-1H-indazol-3-yl)ethanone

IUPAC Name:1-(5-bromo-1H-indazol-3-yl)ethan-1-one

CAS:886363-74-2
Fórmula molecular:C9H7BrN2O
Pureza:95%
Número de catálogo:CM231240
Peso molecular:239.07

Unidad de embalaje Stock disponible Precio($) Cantidad
CM231240-250mg in stock ŤŌ
CM231240-1g in stock ħŤƴ
CM231240-5g in stock ƈǪƈ

Sólo para uso en I+D..

Formulario de consulta

   refresh    

Detalles del producto

Núm. De CAS :886363-74-2
Fórmula molecular:C9H7BrN2O
Punto de fusión:-
Código de sonrisas:CC(C1=NNC2=C1C=C(Br)C=C2)=O
Densidad:
Número de catálogo:CM231240
Peso molecular:239.07
Punto de ebullición:403.8±25.0°C at 760 mmHg
Nº Mdl:MFCD07374362
Almacenamiento:Keep in a tight container and store at 2°C~8°C,protect from light

Category Infos

Indazoles
Indazoles are a class of organic heterocyclic compounds, also known as 1,2-diazaindene and benzopyrazole. Indazole is a good bioisomer of phenol, which is more lipophilic than phenol and less prone to phase I and II metabolism. Indazole derivatives have a wide range of biological activities, and it has been confirmed that indazole compounds have anti-tumor, analgesic, anti-inflammatory and other drug activities. Anticancer is the most important application field of indazole drugs. Renal cell carcinoma, solid tumor, nausea and vomiting caused by chemotherapy and leukemia are the main indications of this structural backbone drug.

Column Infos

Voydeya
Voydeya (danicopan) has been approved in Japan for the treatment of paroxysmal nocturnal haemoglobinuria (PNH). Voydeya is the first drug in the class to be cleared for marketing anywhere in the world and has been licensed for use as an add-on therapy to C5 inhibitors, like its own Soliris (eculizumab) and Ultomiris (ravulizumab) products, in patients who don’t get a satisfactory response from C5 drugs alone. Voydeya (danicopan) is a first-in-class oral Factor D inhibitor. Voydeya has been granted Breakthrough Therapy designation by the US Food and Drug Administration and PRIority MEdicines (PRIME) status by the European Medicines Agency. Voydeya has also been granted Orphan Drug Designation in the US, EU and Japan for the treatment of PNH.

Related Products